| Abatacept for graft vs host disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| allogeneic hematopoietic stem cell transplantation + FLUDARABINE PHOSPHATE + Cyclophosphamide + Mycophenolate Mofetil + Busulfan + Tacrolimus for graft vs host disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Alpha-galactosylceramide for graft vs host disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ATIR101 + T-cell depleted HSCT from a related, haploidentical donor for graft vs host disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Corticosteroids + Ruxolitinib for graft vs host disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cyclophosphamide for graft vs host disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
|---|
| Dapagliflozin for graft vs host disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Decidual Stromal Cells for graft vs host disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Hematopoietic Stem Cell Transplantation + Total Body Irradiation + Cyclophosphamide + Mycophenolate Mofetil + Busulfan + FLUDARABINE + Tacrolimus for graft vs host disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Hematopoietic Stem Cell Transplantation + Total Body Irradiation + Cyclophosphamide + Mycophenolate Mofetil + Tacrolimus for graft vs host disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Peripheral Blood Hematopoietic Cell Transplantation (HCT) + Total body irradiation (TBI) + Cyclophosphamide + Busulfan + FLUDARABINE + FILGRASTIM + Mycophenolate Mofetil Hydrochloride + Sirolimus for graft vs host disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Peripheral Blood Stem Cell Transplantation + Hematopoietic Cell Transplantation + Laboratory Biomarker Analysis + Quality-of-Life Assessment + FLUDARABINE PHOSPHATE + Cyclophosphamide + Mycophenolate Mofetil + Busulfan + Tacrolimus for graft vs host disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| reduced-dose PTCy for graft vs host disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Remestemcel-l for graft vs host disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Rovadicitinib for graft vs host disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ruxolitinib for graft vs host disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Subconjuntival injection of expanded allogenic adult adipose tissue-derived mesenchymal stem cells (ASC for graft vs host disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Total Body Irradiation 12 Gy + Total Body Irradiation 8 Gy for graft vs host disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| αβ T-cells depletion + Cyclophosphamide for graft vs host disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|